• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征相关冠状病毒膜蛋白上免疫显性表位的鉴定

Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus.

作者信息

He Yuxian, Zhou Yusen, Siddiqui Pamela, Niu Jinkui, Jiang Shibo

机构信息

Viral Immunology Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th St., New York, NY 10021, USA.

出版信息

J Clin Microbiol. 2005 Aug;43(8):3718-26. doi: 10.1128/JCM.43.8.3718-3726.2005.

DOI:10.1128/JCM.43.8.3718-3726.2005
PMID:16081901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1234014/
Abstract

Similar to other coronaviruses, the membrane (M) protein of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is a major transmembrane glycoprotein with multiple biological functions. To date, limited information is available about its antigenic properties. In this study, we identified two major immunodominant epitopes on the M protein located in the extreme N-terminal region (residues 1 to 31) and the interior C-terminal region (residues 132 to 161), respectively, by Pepscan analyses against convalescent-phase sera from SARS patients and antisera from virus-immunized mice and rabbits. Synthetic peptides M1-31 derived from the N-terminal epitope and M132-161 derived from the C-terminal epitope were highly reactive with all of the convalescent-phase sera from 40 SARS patients but not with 30 control serum samples from healthy blood donors, suggesting their potential application for serologic diagnosis of SARS. We showed that both peptides (M1-31 and M132-161) were able to induce high titers of antibody responses in the immunized rabbits, highlighting their antigenicity and immunogenicity. These findings provide important information for developing SARS diagnostics and vaccines.

摘要

与其他冠状病毒相似,严重急性呼吸综合征相关冠状病毒(SARS-CoV)的膜(M)蛋白是一种具有多种生物学功能的主要跨膜糖蛋白。迄今为止,关于其抗原特性的信息有限。在本研究中,我们通过针对SARS患者恢复期血清以及病毒免疫小鼠和兔子的抗血清进行肽扫描分析,分别在M蛋白的极端N端区域(第1至31位氨基酸残基)和内部C端区域(第132至161位氨基酸残基)鉴定出两个主要的免疫显性表位。源自N端表位的合成肽M1-31和源自C端表位的合成肽M132-161与40例SARS患者的所有恢复期血清均具有高反应性,但与30份健康献血者的对照血清样本无反应,表明它们在SARS血清学诊断中的潜在应用价值。我们发现这两种肽(M1-31和M132-161)均能在免疫兔子中诱导出高滴度的抗体反应,突出了它们的抗原性和免疫原性。这些发现为开发SARS诊断方法和疫苗提供了重要信息。

相似文献

1
Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus.严重急性呼吸综合征相关冠状病毒膜蛋白上免疫显性表位的鉴定
J Clin Microbiol. 2005 Aug;43(8):3718-26. doi: 10.1128/JCM.43.8.3718-3726.2005.
2
Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.严重急性呼吸综合征(SARS)冠状病毒刺突蛋白免疫显性位点的鉴定:对开发SARS诊断方法和疫苗的意义。
J Immunol. 2004 Sep 15;173(6):4050-7. doi: 10.4049/jimmunol.173.6.4050.
3
Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus.严重急性呼吸综合征冠状病毒核衣壳蛋白上抗原位点的定位
J Clin Microbiol. 2004 Nov;42(11):5309-14. doi: 10.1128/JCM.42.11.5309-5314.2004.
4
Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.鉴定严重急性呼吸综合征冠状病毒刺突糖蛋白S2结构域上一个能够诱导中和抗体的抗原决定簇。
J Virol. 2004 Jul;78(13):6938-45. doi: 10.1128/JVI.78.13.6938-6945.2004.
5
Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates.基于核衣壳蛋白的SARS候选疫苗的免疫学特性
Vaccine. 2006 Apr 12;24(16):3100-8. doi: 10.1016/j.vaccine.2006.01.058. Epub 2006 Feb 8.
6
Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.严重急性呼吸综合征(SARS)相关冠状病毒关键中和决定簇的鉴定:对设计SARS疫苗的重要性。
Virology. 2005 Mar 30;334(1):74-82. doi: 10.1016/j.virol.2005.01.034.
7
A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.一种嵌合多表位DNA疫苗引发了针对严重急性呼吸综合征相关冠状病毒的特异性抗体反应,该反应在体外减弱了SARS-CoV的毒力。
Immunol Lett. 2008 Aug 15;119(1-2):71-7. doi: 10.1016/j.imlet.2008.04.005. Epub 2008 May 19.
8
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.重组杆状病毒表达的严重急性呼吸综合征冠状病毒刺突蛋白的抗原性和免疫原性特征:对疫苗设计的启示
J Virol. 2006 Jun;80(12):5757-67. doi: 10.1128/JVI.00083-06.
9
Identification and antigenic epitope mapping of immunodominant region amino residues 510 to 672 on the spike protein of the severe acute respiratory syndrome coronavirus.严重急性呼吸综合征冠状病毒刺突蛋白上免疫显性区域氨基酸残基510至672的鉴定及抗原表位图谱分析
DNA Cell Biol. 2005 Aug;24(8):503-9. doi: 10.1089/dna.2005.24.503.
10
Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species.不同动物物种血清所识别的严重急性呼吸综合征冠状病毒刺突蛋白和核衣壳蛋白免疫显性区域的确定及应用
J Immunol Methods. 2008 Feb 29;331(1-2):1-12. doi: 10.1016/j.jim.2007.11.009. Epub 2007 Dec 17.

引用本文的文献

1
Direct lipid interactions control SARS-CoV-2 M protein conformational dynamics and virus assembly.直接脂质相互作用控制新冠病毒M蛋白的构象动力学和病毒组装。
bioRxiv. 2024 Nov 5:2024.11.04.620124. doi: 10.1101/2024.11.04.620124.
2
Development and Application of an Indirect Enzyme-Linked Immunosorbent Assay Based on a Recombinant Matrix Protein for the Serological Study of Porcine Deltacoronavirus in Mexican Pigs.基于重组基质蛋白的间接酶联免疫吸附试验的建立及其在墨西哥猪中猪德尔塔冠状病毒血清学研究中的应用。
Vet Med Sci. 2024 Nov;10(6):e70108. doi: 10.1002/vms3.70108.
3
M protein ectodomain-specific immunity restrains SARS-CoV-2 variants replication.M 蛋白胞外结构域特异性免疫抑制 SARS-CoV-2 变体复制。
Front Immunol. 2024 Oct 2;15:1450114. doi: 10.3389/fimmu.2024.1450114. eCollection 2024.
4
Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy.通过高内涵显微镜技术将严重急性呼吸综合征冠状病毒2(SARS-CoV-2)膜蛋白特异性抗体确立为有价值的血清学靶点。
iScience. 2023 Jul 21;26(7):107056. doi: 10.1016/j.isci.2023.107056. Epub 2023 Jun 7.
5
A Candidate Antigen of the Recombinant Membrane Protein Derived from the Porcine Deltacoronavirus Synthetic Gene to Detect Seropositive Pigs.猪德尔塔冠状病毒重组膜蛋白候选抗原基因的合成及其用于检测血清阳性猪的研究
Viruses. 2023 Apr 25;15(5):1049. doi: 10.3390/v15051049.
6
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.传统疫苗开发策略在 SARS-CoV-2 中的应用。
mSystems. 2023 Apr 27;8(2):e0092722. doi: 10.1128/msystems.00927-22. Epub 2023 Mar 2.
7
Recent advances in immunoassay technologies for the detection of human coronavirus infections.免疫分析技术在人类冠状病毒感染检测中的最新进展。
Front Cell Infect Microbiol. 2023 Jan 4;12:1040248. doi: 10.3389/fcimb.2022.1040248. eCollection 2022.
8
Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress.针对人类贝塔冠状病毒的重组蛋白疫苗:策略、方法和进展。
Int J Mol Sci. 2023 Jan 15;24(2):1701. doi: 10.3390/ijms24021701.
9
Structure of SARS-CoV-2 M protein in lipid nanodiscs.SARS-CoV-2 M 蛋白在脂质纳米盘中的结构。
Elife. 2022 Oct 20;11:e81702. doi: 10.7554/eLife.81702.
10
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.传统疫苗研发策略在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)上的应用
ArXiv. 2023 Jan 23:arXiv:2208.08907v2.

本文引用的文献

1
A complete sequence and comparative analysis of a SARS-associated virus (Isolate BJ01).一种与SARS相关病毒(分离株BJ01)的完整序列及比较分析。
Chin Sci Bull. 2003;48(10):941-948. doi: 10.1007/BF03184203.
2
False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide.在重组严重急性呼吸综合征相关冠状病毒(SARS-CoV)核衣壳酶联免疫吸附测定中,因HCoV-OC43和HCoV-229E导致的假阳性结果,通过用重组SARS-CoV刺突多肽进行蛋白质免疫印迹法得以纠正。
J Clin Microbiol. 2004 Dec;42(12):5885-8. doi: 10.1128/JCM.42.12.5885-5888.2004.
3
Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry.灭活的严重急性呼吸综合征冠状病毒(SARS-CoV)疫苗可引发高滴度的刺突蛋白特异性抗体,这些抗体可阻断受体结合和病毒进入。
Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52. doi: 10.1016/j.bbrc.2004.10.052.
4
Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus.严重急性呼吸综合征冠状病毒核衣壳蛋白上抗原位点的定位
J Clin Microbiol. 2004 Nov;42(11):5309-14. doi: 10.1128/JCM.42.11.5309-5314.2004.
5
The expression of SARS-CoV M gene in P. Pastoris and the diagnostic utility of the expression product.严重急性呼吸综合征冠状病毒M基因在巴斯德毕赤酵母中的表达及其表达产物的诊断效用
J Virol Methods. 2004 Dec 1;122(1):105-11. doi: 10.1016/j.jviromet.2004.08.015.
6
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine.严重急性呼吸综合征冠状病毒刺突蛋白的受体结合域诱导高效中和抗体:对开发亚单位疫苗的启示
Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81. doi: 10.1016/j.bbrc.2004.09.106.
7
Detection of antibodies against SARS-CoV in serum from SARS-infected donors with ELISA and Western blot.采用酶联免疫吸附测定(ELISA)和蛋白质印迹法检测严重急性呼吸综合征(SARS)感染供体血清中抗SARS冠状病毒(SARS-CoV)的抗体。
Clin Immunol. 2004 Nov;113(2):145-50. doi: 10.1016/j.clim.2004.07.003.
8
Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine.针对严重急性呼吸综合征相关冠状病毒的保护性体液免疫反应:对有效蛋白质疫苗设计的启示
J Gen Virol. 2004 Oct;85(Pt 10):3109-3113. doi: 10.1099/vir.0.80111-0.
9
Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.严重急性呼吸综合征(SARS)冠状病毒刺突蛋白免疫显性位点的鉴定:对开发SARS诊断方法和疫苗的意义。
J Immunol. 2004 Sep 15;173(6):4050-7. doi: 10.4049/jimmunol.173.6.4050.
10
A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.皮下注射紫外线灭活的严重急性呼吸综合征冠状病毒疫苗可在小鼠体内引发全身性体液免疫。
Int Immunol. 2004 Oct;16(10):1423-30. doi: 10.1093/intimm/dxh143. Epub 2004 Aug 16.